Loading…
← CockpitCompetitor Analysis › ARGX argenx SE Sponsored ADROpen in the cockpit ↗

argenx SE Sponsored ADRARGXCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology

Belgian biotech developing antibody therapies for autoimmune diseases, led by Vyvgart for myasthenia gravis and other neuromuscular conditions.

Momentum strong 69
Mkt cap
$59.1B
US dollars, full cap
Free float
100%
of shares outstanding
$/day
$353M
20-day average traded
Fwd P/E
29.0×
forward earnings
ROIC−WACC
+28.8 pp
WACC 7.5%
Hurdle
-140 pp
Req g minus delivered
Next earnings
99 days
25 Feb 2027
Close · USD$941.25
1D-0.7%
1W-3.7%
1M+8.2%
3M-9.3%
6M+17.0%
YTD+11.9%
1Y+1.2%
ATR %3.0%
Beta0.52
52w lowhigh12.3% off high

What argenx SE Sponsored ADR does

Belgian biotech developing antibody therapies for autoimmune diseases, led by Vyvgart for myasthenia gravis and other neuromuscular conditions.

Nearly all revenue is Vyvgart, sold as an intravenous and a self-injected under-the-skin version, mainly in the US through its own commercial team, with partners elsewhere, including Zai Lab in China. Its own antibody-discovery research feeds the pipeline. Incorporated in the Netherlands, it is based in Belgium.

Products and services

  • Vyvgart (myasthenia gravis, CIDP)
  • Pipeline: additional autoimmune indications

Customers

  • Neurologists/immunologists treating autoimmune dis
  • Patients with rare autoimmune conditions

Where it sits in the supply chain

  • Healthcare
  • Biotechnology
  • Antibody-based autoimmune drug…

What could go right

  • Vyvgart indication expansion driving revenue growth
  • Pipeline readouts in additional autoimmune diseases

What could go wrong

  • Single-drug revenue concentration (Vyvgart)
  • Competitive FcRn-inhibitor entrants

Moat: narrow (IP / patents, regulatory licence). First-in-class FcRn-blocker approved in a growing list of autoimmune indications, protected by patents.

Headquarters: Ghent, Belgium · Founded: 2008 · Employees: 1,863

Named competitors

argenx SE Sponsored ADR at a glance

Size argenx SE Sponsored ADR (ARGX) is a United States Health Care company (Biotechnology) with a market value of $59.1B, the 223rd largest of 3,085 United States companies the cockpit tracks. Shares closed at $941.25 on 18 Nov 2026.

Performance Over six months the shares gained 17.0%, against +32.7% for the median peer and -2.2% for the United States market (cap-weighted) — 7th lowest of 15 in its peer set.

Growth Revenue grew 70.6% over the last twelve months (peer median +11.0%); the operating margin is 28.8% (peer median 25.1%).

Valuation It trades at 29.0× forward earnings against a peer median of 25.2× (5th most expensive of 11).

Price implies For today's price to make sense, revenue must grow about 12% a year for seven years (Req g). Recent delivered growth is +151%, so the hurdle is -140 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 28.8 points above its cost of capital (7.5% WACC).

Short interest Short interest is 2.2% of the free float (30 Oct 2026).

Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012021 May 202621 Aug 202618 Nov 2026Peer median 132ARGX 115
Six months, rebased to 100: argenx SE Sponsored ADR against the median of its 14 peers (local-currency closes).

argenx SE Sponsored ADR financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$5.22B$4.17B$2.19B$1.23B$411M
Revenue growth—+91%+78%+199%—
Gross profit$4.67B$3.69B$1.95B$1.00B$277M
EBITDA$1.54B$1.02B-$46.4M-$340M-$642M
Net income$1.71B$1.30B$832M-$296M-$710M
Free cash flow$1.16B$844M$27.1M-$329M-$851M
Capital expenditure$70.0M$112M$68.2M$43.9M$104M
Total debtn/a$47.2M$39.1M$20.0M$12.4M

Quarterly statements and history in the cockpit →

argenx SE Sponsored ADR competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%+200%+300%-20%0%+20%CSLLONN207940MRNAIQVNTRAGMABUTHR2269BNTXNBIXBBIOARGX6-month return →1-month return →
Up and to the right = strong over both horizons. argenx SE Sponsored ADR is the large dot.

Fundamentals: revenue growth against valuation

-25%0%+25%+50%+75%20×30×40×CSLLONN207940IQV068270GMABUTHR2269GILDNBIXARGXRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. argenx SE Sponsored ADR is the large dot.

Capital: growth delivered against growth the price implies

0%+50%+100%+150%0%50%100%150%CSLLONN207940068270UTHR2269ARGXGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. argenx SE Sponsored ADR is the large dot.

argenx SE Sponsored ADR competitors and peer comparison

Head to head with its named competitors (ARGX vs JNJ vs AZN.L vs IMVT)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
argenx SE Sponsored ADR ARGX$59.1B+17%+71%29%29.0×11.7%
Johnson & Johnson JNJ$656B+20%+8%26%24.2×3.7%
AstraZeneca AZN.L$278B-2%+5%23%17.6×14.4%
Immunovant IMVT$6.86B-7%n/an/an/an/a
Regeneron Pharmaceuticals REGN$97.8B+46%+19%30%11.8×-1.1%
Amgen AMGN$240B+34%+9%36%18.3×1.6%
Dianthus Therapeutics DNTH$4.73B-5%-12%-8,684%n/an/a

How argenx SE Sponsored ADR compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

argenx SE Sponsored ADR against its 14 peers (data as of 18 Nov 2026)
MeasureARGXPeer medianRank in peer set
1-month return+8.2%+2.9%4th highest of 15
6-month return+17.0%+32.7%7th lowest of 15
Distance from 52-week high-12.3%-12.8%7th highest of 15
Revenue growth (TTM)+70.6%+11.0%2nd highest of 15
Operating margin28.8%25.1%7th highest of 15
Forward P/E29.0×25.2×5th most expensive of 11
Growth the price implies (Req g, 7 yrs)11.7%8.8%4th most demanding of 11
Growth delivered (Del g)+151.4%+17.1%highest of 11
Hurdle (Req g minus delivered)-139.7 pp-7.5 ppleast demanding of 11
ROIC minus cost of capital+28.8 pp+2.2 pphighest of 15
EV / EBITDA35.1×16.4×most expensive of 11
Net debt / EBITDA-3.3×1.2×least indebted of 11

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
argenx SE Sponsored ADR ARGXUnited States$59.1B+17%+71%29%29.0×11.7%+151.4%
CSL CSL.AXAustralia$63.7B+102%-2%26%21.5×6.8%+11.0%
Lonza LONN.SWSwitzerland$53.9B+36%-11%25%36.1×15.6%+7.7%
Samsung Biologics 207940.KSSouth Korea$48.7B-6%-20%43%34.4×7.0%+31.4%
Moderna MRNAUnited States$79.6B+309%+13%-116%n/an/an/a
Iqvia IQVUnited States$42.5B+50%+9%14%18.7×16.8%+7.5%
Natera NTRAUnited States$42.0B+41%+37%-9%n/an/an/a
Celltrion 068270.KSSouth Korea$34.9B+12%+40%32%33.9×10.6%+17.6%
Genmab A/S GMAB.CODenmark$30.8B+103%+15%31%40.9×11.6%+19.5%
United Therapeutics UTHRUnited States$24.6B+2%+2%44%23.9×0.3%+16.5%
Wuxi Bio 2269.HKHong Kong$23.1B+35%+22%32%26.5×20.8%+30.2%
BioNTech SE Sponsored ADR BNTXUnited States$20.6B-8%-21%-61%n/an/an/a
Gilead Sciences GILDUnited States$210B+30%+7%38%19.9×-2.4%+3.6%
Neurocrine Biosciences NBIXUnited States$16.5B+5%+38%25%18.0×-1.5%+22.3%
BridgeBio Pharma BBIOUnited States$15.2B+14%+167%-37%n/an/an/a

Questions

Who are argenx SE Sponsored ADR's main competitors?
Named competitors: UCB (private or unlisted), Johnson & Johnson (nipocalimab) (JNJ), AstraZeneca (Alexion) (AZN.L), Immunovant (IMVT), Regeneron Pharmaceuticals (REGN), Amgen (AMGN). The cockpit's measured peer set (industry) also includes CSL (CSL.AX), Lonza (LONN.SW), Samsung Biologics (207940.KS), Moderna (MRNA), Iqvia (IQV), Natera (NTRA).
Is argenx SE Sponsored ADR expensive compared with its peers?
On forward p/e it trades at 29.0× against a peer median of 25.2×, 5th most expensive of 11 in its peer set. For today's price to make sense, revenue must grow about 12% a year for seven years (Req g). Recent delivered growth is +151%, so the hurdle is -140 pp: the price already allows for a slowdown.
How has argenx SE Sponsored ADR stock performed?
Over six months to 18 Nov 2026 the shares returned +17.0% against +32.7% for the median peer; over one year +1.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.